Preclinical safety assessment of ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer

Human Gene Therapy Clinical Development

Volumn 25, Issue 1, 2014, Pages 7-15

  Schenk, Ellen ^a   Essand, Magnus ^b   Kraaij, Robert ^a   Adamson, Rachel ^c   Maitland, Norman J ^c   Bangma, Chris H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; RISK ASSESSMENT; TOXICITY; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CONSUMER PRODUCT SAFETY; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904427932     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2013.181     Document Type: Article

References (26)

1. Adamson, R.E., Frazier, A., Evans, H., et al. (2012). In vitro primary cell culture as a physiologically relevant method for pre-clinical testing of human oncolytic adenovirus. Hum. Gene Ther. 23, 218-230.
2. Au, T., Thorne, S., Korn, W.M., et al. (2007). Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther. 14, 139-150.
3. Barton, K.N., Stricker, H., Brown, S.L., et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther. 16, 1761-1769.
4. Carlisle, R.C., Di, Y., Cerny, A.M., et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909-1918.
5. Cheng, W.S., Giandomenico, V., Pastan, I., and Essand, M. (2003). Characterization of the androgen-regulated prostatespecific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter. Endocrinology 144, 3433-3440.
6. Cheng, W.S., Kraaij, R., Nilsson, B., et al. (2004). A novel TARPpromoter- based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol. Ther. 10, 355-364.
7. Cheng, W.S., Dzojic, H., Nilsson, B., et al. (2006). An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther. 13, 13-20.
8. DeWeese, T.L., van der Poel, H., Li, S., et al. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472.
9. Djavan, B., Moul, J.W., Zlotta, A., et al. (2003). PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur. Urol. 43, 12-27.
10. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374-1403.
11. Freytag, S.O., Khil, M., Stricker, H., et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968-4976.
12. Freytag, S.O., Stricker, H., Pegg, J., et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose threedimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497-7506.
13. Freytag, S.O., Movsas, B., Aref, I., et al. (2007a). Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 15, 1016-1023.
14. Freytag, S.O., Stricker, H., Peabody, J., et al. (2007b). Five-year follow-up of trial of replication-competent adenovirusmediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 15, 636-642.
15. He, T.C., Zhou, S., da Costa, L.T., et al. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514.
16. Kraaij, R., van Weerden, W.M., de Ridder, C.M., et al. (2002). Validation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab. Anim. 36, 165-172.
17. Lion, T., Baumgartinger, R., Watzinger, F., et al. (2003). Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102, 1114-1120.
18. Maitland, N., Chambers, K., Georgopoulos, L., et al. (2010). Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems? Hum. Gene Ther. 21, 815-827.
19. Marques, R.B., van Weerden, W.M., Erkens-Schulze, S., et al. (2006). The human PC346 xenograft and cell line panel: amodel system for prostate cancer progression. Eur. Urol. 49, 245-257.
20. Nemunaitis, J., Cunningham, C., Buchanan, A., et al. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746-759.
21. Schenk, E., Essand, M., and Bangma, C. (2010). Clinical adenoviral gene therapy for prostate cancer. Hum. Gene Ther. 21, 807-813.
22. Seidemann, K., Heim, A., Pfister, E.D., et al. (2004). Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am. J. Transplant. 4, 2102-2108.
23. Seymour, L.W., and Fisher, K.D. (2009). Preclinical screening of gene therapy in human tissues. Hum. Gene Ther. 20, 291-292.
24. Small, E.J., Carducci, M.A., Burke, J.M., et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostatespecific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14, 107-117.
25. Sukumar, S., Rogers, C.G., Trinh, Q.D., et al. (2013). Oncological outcomes after robot-assisted radical prostatectomy: long term follow-up in 4,803 patients. BJU Int. In press. DOI: 10.1111/bju.12404
26. van Weerden, W.M., Bangma, C., and de Wit, R. (2009). Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br. J. Cancer 100, 13-18.